End-Stage age-related macular degeneration (AMD) is the most advanced form of AMD and the leading cause of legal blindness in older Americans. This irreversible retinal disease can develop from either the wet or dry earlier stages of AMD. It results in a loss of central vision, or blindspot, uncorrectable by glasses, drugs, or cataract surgery.(1) Currently, there is no known treatment that can cure End-Stage AMD.(2)

According to National Eye Institute statistics, advanced age-related macular degeneration (AMD) in one or both eyes with associated vision loss affected approximately 1.8 million people in the U.S. in the year 2000 - we estimate that number now exceeds 2 million. Another 7.3 million people are reported to be at substantial risk for vision loss from AMD. Due to the rapid aging of the U.S. population this number is expected to double by the year 2050.(3)

Age-related macular degeneration (AMD) is most common in people 65 years of age and older. Although individuals with AMD do not generally go completely blind, many people whose AMD has advanced find it difficult to read, recognize people, drive, and perform other everyday functions that require central vision.

VisionCare will create value for the ophthalmic community by providing them the opportunity to offer their End-Stage AMD patients improved vision and quality of life through a first-of-kind treatment program. Learn more

Investor Inquiries:
(408) 872-9393


1. Forooghian F, Agrón E, Clemons TE, Ferris FL 3rd, Ch ew EY; Age-Related Eye Disease Study Research Group. Visual acuity outcomes after cataract surgery in patients with age-related macular degeneration: age-related eye disease study report no. 27. Ophthalmology. 2009;116:2093-100.

2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-17.

3. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting Age-Related Macular Degeneration Through the Year 2050: The potential impact of n ew treatments. Arch Ophthalmol. 2009;127:533-540.

Restore the Center of Your World

The CentraSight™ treatment program uses the only FDA-approved telescope prosthesis to improve visual acuity in patients with End-Stage age-related macular degeneration (AMD).